 |
||||||||||||||
|
|
NDC numbers for HepaGam B As of August 1, 2010, HepaGam B will have new NDC numbers. Use these new numbers when ordering and submitting insurance claims. If you have or receive product with the old NDC numbers, continue to use it until supplies are depleted. Do not delete the old NDC numbers from your system. Specific J Codes for reimbursement of HepaGam B* Code J 1573† HepaGam B INTRAMUSCULAR Injection: Code J1571† For reimbursement support, call 1-877-HepaGam B (437-2426) Reimbursement support is available for healthcare providers, medical billing staff and patients. For more information, including questions on reimbursement please contact the customer service line at 1-877-HepaGam B (437-2426) press option 2. For medical inquires, please contact Medical Affairs at 1-800-768-2304. * As of July 2008, HepaGam B qualifies for pass-through status under the hospital OPPS Update. Some payers use ASP methodology to calculate reimbursement (eg, Medicare, some Medicaid and some private insurers). Please consult with the HepaGam B Reimbursement Hotline if you have questions. |
|
HepaGam B [Hepatitis B Immune Globulin Intravenous (Human)] is a sterile solution of gamma globulin (IgG) made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Individuals known to have severe, potentially life-threatening reaction to human globulin preparations should not receive HepaGam B or any other immune globulin (human). Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have severe, potentially life-threatening allergic reactions. The maltose contained in HepaGam B can interfere with some types of blood glucose monitoring systems. Only testing systems that are glucose-specific should be used in patients receiving HepaGam B. This interference can result in falsely elevated glucose readings that can lead to untreated hypoglycemia or to inappropriate insulin administration, resulting in life-threatening hypoglycemia. The most common expected adverse drug reactions for immune globulins like HepaGam B are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain. For post-exposure prophylaxis indications, HepaGam B must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B should be given only if the expected benefits outweigh the potential risks. |
||
|
||
